The Oral GLP-1 Pill Race: Rybelsus, Orforglipron & 2026 Weight-Loss Tablets
By Dr. Sarah Mitchell, Respiratory Equipment Specialist & Wellness Editor · Published 2026-08-14 · 8 min read
Injections dominated GLP-1 headlines. In 2026, once-daily pills are catching up. What orforglipron, oral semaglutide 25 mg, and amycretin will change.
No Needles, Similar Results
- Orforglipron (Eli Lilly) — small-molecule oral GLP-1, ~14.7% weight loss at 72 weeks in ATTAIN-1.
- Oral semaglutide 25 mg (OASIS-4) — ~13.6% weight loss, food/water timing rules relaxed vs Rybelsus 2019.
- Amycretin (Novo) — dual GLP-1/amylin, phase 2 showed 22% loss in 36 weeks.
Practical Trade-Offs
Pills avoid injection anxiety but require strict fasting for peptide-based options. Small-molecule pills (orforglipron) do not.
---
Round Out Your Home Health Setup
Pair the latest wellness protocols with clinical-grade monitoring. Browse portable oxygen concentrators, CPAP machines, and respiratory accessories — or call our respiratory therapists at (877) 699-4365 for a free consult.